182.03

2.76% 4.89

After Hours: 182.03

Krystal Biotech Inc (KRYS)

Overview News Price History Option Chain Financials Why KRYS Down? Discussions Forecast

Krystal Biotech Inc stock is traded at $182.03, with a volume of 212.53K. It is up +2.76% in the last 24 hours and down -6.71% over the past month. Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Previous Close:

$177.14

Open:

$176.4

24h Volume:

212.53K

Relative Volume:

0.79

Market Cap:

$5.17B

Revenue:

Net Income/Loss:

$57.16M

P/E Ratio:

-123.83

EPS:

-1.47

Net Cash Flow:

$-54.44M

1W Performance:

+1.03%

1M Performance:

-6.71%

6M Performance:

+2.30%

1Y Performance:

+56.92%

1-Day Range:

$176.25

$183.92

1-Week Range:

$176.22

$183.92

52-Week Range:

$93.95

$219.34

Krystal Biotech Inc Stock (KRYS) Company Profile

Name

Krystal Biotech Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(412) 586-5830

Address

2100 WHARTON STREET, PITTSBURGH, PA

Employee

229

Twitter

@KrystalBiotech

Next Earnings Date

2024-08-05

Latest SEC Filings

KRYS's Discussions on Twitter

Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-23	Initiated	Goldman	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-12-23	Initiated	Citigroup	Buy
Sep-07-23	Initiated	Berenberg	Buy
Apr-18-23	Initiated	Stifel	Buy
Feb-28-23	Upgrade	Goldman	Neutral → Buy
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-18-22	Initiated	BofA Securities	Buy
Jul-20-21	Upgrade	Goldman	Neutral → Buy
Sep-18-20	Initiated	B. Riley FBR	Buy
Jun-04-20	Initiated	Evercore ISI	Outperform
Sep-24-19	Initiated	Goldman	Neutral
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jun-24-19	Reiterated	Chardan Capital Markets	Buy
Jun-24-19	Reiterated	H.C. Wainwright	Buy
May-30-19	Initiated	Guggenheim	Buy
Sep-11-18	Initiated	Cantor Fitzgerald	Overweight

View All

Krystal Biotech Inc Stock (KRYS) Latest News

03:58 AM

Sei Investments Co. Increases Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat

03:58 AM

Sep 29, 2024

Ensign Peak Advisors Inc Sells 14,348 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat

Sep 29, 2024

Sep 27, 2024

Amalgamated Bank Acquires 6,847 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat

Sep 27, 2024

Sep 24, 2024

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal - Benzinga

Sep 24, 2024

54,656 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Acquired by Public Sector Pension Investment Board - MarketBeat

Sep 24, 2024

Sep 23, 2024

Top investors say Krystal Biotech Inc (KRYS) ticks everything they need - SETE News

Sep 23, 2024

Avoro Capital Advisors LLC Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World

Sep 23, 2024

Investor’s Delight: Krystal Biotech Inc (KRYS) Closes Weak at 184.17, Down -0.17 - The Dwinnex

Sep 23, 2024

Krystal Biotech, Inc. (NASDAQ:KRYS) Position Increased by Integral Health Asset Management LLC - Defense World

Sep 23, 2024

Integral Health Asset Management LLC Has $15.61 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat

Sep 23, 2024

Sep 21, 2024